Oragenics, Lantern Bioworks forge partnership for replacement-therapy assets
In a landmark collaboration, Oragenics, Inc. (NYSE American: OGEN) and Lantern Bioworks have sealed a groundbreaking partnership through a formal materials transfer agreement. This milestone comes after rigorous testing and validation of Oragenics’ biological samples, poised to potentially revolutionize dental caries prevention by replacing harmful bacterial strains with non-pathogenic counterparts. As part of this agreement, […]